Why GSK (GSK) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK's shares stuck in the middle lane
GSK PLC's (LSE:GSK, NYSE:GSK) latest quarter looked strong enough on pape, but the share price barely moved. The drugmaker has spent much of the past decade trapped between £15 and £18, and Deutsche Bank thinks that pattern is unlikely to change soon.
GSK delivers one of its cleaner beats, says leading bank
After Wednesday's results, GSK PLC (LSE:GSK, NYSE:GSK) looks to have delivered one of its cleaner beats in recent quarters. Third-quarter numbers were comfortably ahead of expectations, with sales up 4% on consensus and core operating profit 12% higher.
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
GSK plc (GSK) Q3 2025 Earnings Call Transcript
GSK plc ( GSK ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Emma Walmsley - CEO & Director Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO of ViiV Healthcare & President of Global Health Julie Brown - CFO & Executive Director Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants Peter Verdult - BNP Paribas Exane, Research Division Matthew Weston - UBS Investment Bank, Research Division Michael Leuchten - Jefferies LLC, Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Sachin Jain - BofA Securities, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Sarita Kapila - Morgan Stanley, Research Division Zain Ebrahim - JPMorgan Chase & Co, Research Division Presentation Operator Ladies and gentlemen, a very warm welcome to the GSK Q3 2025 Results Call.
GSK raises its sights after strong quarter and upgraded outlook
GSK PLC's (LSE:GSK, NYSE:GSK) third-quarter results offered the kind of clean beat investors like to see. Sales came in 4% ahead of UBS forecasts, with operating profit up 12% and strength visible across all three divisions: Specialty Medicines, Vaccines and General Medicines.
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
GSK (GSK) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.27 per share a year ago.
GSK lifts profit outlook after strong quarter and upbeat broker reaction
GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% to 1,707p after the pharmaceutical group raised its full-year guidance and delivered quarterly results that topped forecasts across almost every metric. The upbeat figures, helped by a strong performance in Specialty Medicines and vaccines, also prompted positive analyst commentary, with Jefferies reaffirming its 'buy' rating and setting a price target of 2,000p.
GSK Raises Guidance After Sales, Earnings Growth
The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.
GSK hikes outlook as sales and earning grow faster than expected
GSK PLC (LSE:GSK, NYSE:GSK) raised its outlook for the full year after beating expectations with third-quarter revenues and earnings per share. Group revenues for the FTSE 100 drugmaker came in at £8.55 billion for the quarter to the end of September, up 7% on the same period last year and topping the average City forecast of £8.28 billion.
GSK raises 2025 sales forecast after strong growth in specialty medicines
GSK raised its 2025 sales expectations on Wednesday after third-quarter results beat expectations, driven by double-digit growth in its specialty medicines, including HIV and oncology.
Here's Why GSK (GSK) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
